Multiple myeloma - bortezomib

Summary

This guidance recommends bortezomib monotherapy as a possible treatment for progressive multiple myeloma for people:

• whose multiple myeloma has relapsed for the first time after having one treatment, and
• who have had a bone marrow transplant, unless it is not suitable for them.
• After not more than four cycles of treatment, a blood or urine test should be done to check how well the cancer has responded to bortezomib.
• Treatment should be continued only if there has been at least a partial response to the drug.

Documents

For healthcare professionals

• TA129 Multiple myeloma - bortezomib: Quick Ref Guide
• TA129 Multiple myeloma - bortezomib: Guidance (MS word format)
• TA129 Multiple myeloma - bortezomib: Guidance

For patients, carers and the public

• TA129 Multiple myeloma - bortezomib: Understanding NICE guidance (MS word format)
• TA129 Multiple myeloma - bortezomib: Understanding NICE guidance

Background information

• NICE guidance on bortezomib (Velcade) is a win-win solution for multiple myeloma patients and the NHS

Implementing this guidance

Any further information NICE has produced to help the NHS implement this guideline locally is linked to below:

• Multiple myeloma - bortezomib: Audit criteria
• Multiple myeloma - bortezomib: Costing template